By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



Vallongatan 1

Uppsala    SE-752 28  Sweden
Phone: 46-18-50-54-40 Fax: 46-18-51-08-73



Company News
Oasmia Has Submitted A Marketing Authorization Application To The European Medicines Agency For Its Lead Cancer Product Apealea (Paclical) 2/8/2016 6:18:44 AM
Oasmia Makes Key Hires; Strengthens Organizational Structure Entering Commercial Phase 2/3/2016 6:42:16 PM
Oasmia Receives Order Of $7.5 Million In End-User Value For The Russian Market 10/30/2015 6:48:49 AM
Oasmia Announces Pricing Of Public Offering Of American Depositary Shares And NASDAQ Listing 10/29/2015 12:48:03 PM
Oasmia Executes First Commercial Order Of Paclical For The Russian Market 10/28/2015 7:09:04 AM
Oasmia Announces Commercial Launch Of Paclical In Russia And CIS Countries 10/5/2015 7:24:15 AM
Swedish Cancer Biotech Oasmia Narrows Range For IPO 9/16/2015 11:53:40 AM
Oasmia's Paclical Does Well in Head to Head Study with Celgene (CELG)'s Abraxane 8/4/2015 6:06:51 AM
Oasmia Launches U.S. Brand And Sales Platform 7/7/2015 7:14:13 AM
Oasmia Files for $23 Million IPO 7/7/2015 6:03:55 AM